Financial Trends -- 4/10

Revenue inflected positive in Q2 2025 after six straight quarters of decline. The trajectory tells the cyclical story cleanly: Q1 2024 printed -25.7% YoY; by Q3 2025 growth had re-accelerated to +22.8%. Q4 2025 decelerated to +5.6% as U.S. phosphate demand collapsed on affordability concerns (per CEO Bodine on the Q4-25 call). Q1 2026 re-accelerated to +14.4% with spring planting, but this masks the bifurcated reality below the top line.

Phosphate EBITDA fell -23% despite DAP prices rising +15% -- the most concerning data point in MOS's profile. Potash (+25.3%) and Mosaic Fertilizantes (+64.8%) carried the year, masking deep operational deterioration in the largest segment. The Phosphate franchise is not earning its cost of capital: sulfur and ammonia raw material costs spiked, U.S. operational issues (Riverview, Bartow, New Wales turnaround, hurricane disruption) constrained volumes -7.8% YoY, and management is now "revisiting production plans" because raw material economics no longer work at current DAP prices.

Phosphate EBITDA collapsed from $341M (Q4 24) to $115M (Q1 26) -- a -66% drop -- while DAP averaged +12% over the same span. This is the single most concerning data point in MOS. The classic commodity-cycle thesis (rising prices = expanding margins) is broken in U.S. phosphate. Q1 2026 sulfur shock plus the New Wales turnaround compressed the quarter. Bull case requires phosphate cost normalization in 2H 2026 and capex rolling off as restoration projects complete; bear case is that the asset base is permanently disadvantaged.

Potash performed exactly as a healthy commodity recovery should look. MOP price troughed at $199/t in Q4 2024, rallied +33% to $264 by Q4 2025, and held at $265 in Q1 2026. Volumes were +3% YoY with EBITDA up +58% from Q4 2024 to Q4 2025. This is the 22% of MOS that lives inside the genuine potash oligopoly (Nutrien/MOS/Belaruskali/Uralkali), and it shows. Global supply remains "very tight" per management on the Q1-26 call, with Belarus/Russia exports constrained.

Q1 2026 EBITDA of $416M is the weakest in the cycle excluding 2024 troughs. Down -24% YoY from Q1 2025's $544M -- and this is the ADJUSTED number (i.e. after stripping out the $422M Brazilian impairment). The underlying business is weakening even as headline revenue accelerates. Q3 2025's $806M now looks like the cycle peak; Q1 26 confirms phosphate cost pressure and Brazil portfolio cleanup are eating into the price-driven recovery.

Q1 2026 GAAP EPS of -$0.81 (adj $0.05) reflects the sulfur shock plus Brazilian impairments. EPS recovered strongly through 2025 -- $0.75 in Q1, $1.29 in both Q2 and Q3, on track to deliver FY2025 EPS of [$1.70](https://daloopa.com/src/159551825) (+209% YoY off the depressed $0.55 base). Then Q1 2026 swung to a -208% YoY GAAP loss driven by the -$422M Mosaic Fertilizantes operating loss (writedowns on Patos de Minas, Taquari, pending Carlsbad divestitures) and weaker Phosphate. While impairments are non-cash, they signal prior-cycle capital was misallocated.

FCF turned negative in 3 of the last 4 quarters -- triggering the mandatory -2.0 score penalty. Q3 2025 (-$135M), Q4 2025 (-$535M), Q1 2026 (-$253M) -- cumulative ~-$365M over the trailing four quarters. The two drivers are (1) elevated capex of $1.4B-plus annually as MOS funds U.S. phosphate restoration and Brazil expansion (Q4-25 capex alone was [$1,359M](https://daloopa.com/src/158286557)), and (2) working capital absorption tied to inventory build. Per CEO, capex moderates in 2026 as restoration spend rolls off -- but the cash burn is happening at a moment of weakening earnings.

Total debt grew $1.3B (+31%) in five quarters versus revenue +8% -- triggering the -1.0 penalty. MOS issued [$900M of new long-term debt in Q4 2025](https://daloopa.com/src/158297081) to fund capex and working capital. Net Debt/EBITDA on FY2025 EBITDA of $2.42B is a manageable ~2.1x, but on a Q1 2026 run-rate ($416M annualized = $1.66B) net leverage would be ~3.3x -- approaching the level where covenants and rating agencies start to ask questions. The combination of negative FCF + rising debt at a cycle inflection is the textbook signature of a balance sheet under stress.

MOS is exhibiting the classic "early cyclical" tape -- prices recovering, top line inflecting, Potash and Brazil EBITDA up sharply -- but underlying earnings quality is poor and getting worse. The Phosphate franchise (the largest segment) saw EBITDA fall -23% in 2025 despite DAP prices up +15%. FCF was negative in 3 of the last 4 quarters. Total debt grew +31% in 5 quarters versus revenue +8%. Q1 2026 printed -$0.81 GAAP EPS with a -$422M Brazilian impairment and a sulfur cost shock that has management revisiting production plans. Bull case requires Phosphate cost normalization in 2H 2026 and capex roll-off; bear case is that MOS is a structurally lower-return business than the 2021-2023 cycle suggested. Score of 4/10 reflects mandatory penalties for negative FCF (-2.0) and debt growing faster than revenue (-1.0) -- two of the three quality gates explicitly fail.